Overview of Dr. Krop
Ian Krop, MD, PhD is the Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research at the Yale Cancer Center. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).
Dr. Krop received his undergraduate, medical and PhD degrees from Johns Hopkins University. He subsequently completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in hematology and medical oncology at Dana-Farber.
Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan
Office
35 Park Street
Smilow Cancer Hospital at Yale-New Haven
New Haven, CT 06511
Education & Training
- Johns Hopkins University School of MedicinePhD, 1996
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
- Johns Hopkins University School of MedicineResidency, 1996 - 1999
- Johns Hopkins University School of MedicineClass of 1996
Certifications & Licensure
- FL State Medical License 2023 - Present
- CT State Medical License 2022 - 2025
- MA State Medical License 2002 - 2023
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 259 citationsSystemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Gu...Sharon H. Giordano, Sarah Temin, Jeffrey J. Kirshner, Sarat Chandarlapaty, Jennie R. Crews
Journal of Clinical Oncology. 2014-05-05 - 333 citationsTrastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall surviv...Ian E. Krop, Sung Bae Kim, Antonio Gonzalez Martin, Patricia LoRusso, Jean-Marc Ferrero
The Lancet. Oncology. 2017-06-01 - 376 citationsTrastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of f...Véronique Diéras, David Miles, Sunil Verma, Mark D. Pegram, Manfred Welslau
The Lancet. Oncology. 2017-06-01
Press Mentions
- Maximizing ADCs in Breast Cancer: Targets, Sequencing, and MoreJune 13th, 2023
- Will HER3 Targeting Change Breast Cancer Care?July 6th, 2023
- Palliative Care for Lung Cancer Via Video? Telehealth “Very Viable Option,” Study ShowsJune 5th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: